GENE ONLINE|News &
Opinion
Blog

2021-11-10| Special

Experts Weigh on How COVID Vaccine Development Has Prepared Us for the Next Pandemic

by Sahana Shankar
Share To
The COVID-19 pandemic was a major disruptive force to propel major innovation, scale, and capacity building in vaccine development. The last two years have seen an unprecedented acceleration in vaccine research, regulatory approvals, and consumer readiness. In a panel discussion titled “Future of Vaccines’,  at the Financial Times Global Pharmaceutical and Biotechnology Conference, industry experts shared their lessons from the COVID-19 pandemic.

The panel, moderated by Greg Reh, Global Life Sciences and Healthcare Industry leader, Deloitte, comprised of

Judy Stewart, Senior Vice President, Head of US vaccines, GlaxoSmithKline Lovisa Afzelius, Origination Partner, Flagship Pioneering Nell Beattie, Chief Business Officer, VBI Vaccines Rasmus Bech Hansen, Co-Founder, and CEO, Airfinity

It's free! Log in now to read

LATEST
Orna Therapeutics Secures Multi-Billion RNA Deal With Merck After $221 Million Series B
2022-08-17
FDA Allows Sales of Over-the-Counter Hearing Aids After Five Years of Consideration
2022-08-17
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
GSK’s Second Billion Dollar Acquisition Outprices their First of 2022
2022-08-16
Despite Global Acceptance, The UK Refuses to Buy AstraZeneca’s Evusheld, Citing ‘Insufficient Data’
2022-08-16
Antibody Treatment for Multiple Varieties of CoronaVirus
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-14
The Future of Health
Online
2022-09-14
Bio Asia Pacific 2022
Tailand
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!